Why the study?
Peri-interventional myocardial injury occurs frequently during TAVI, prompting investigation into whether remote ischemic preconditioning could reduce myocardial injury, acute kidney injury, and mortality.
Does remote ischemic preconditioning reduce myocardial injury, acute kidney injury, or 6-month mortality in patients undergoing TAVI?
Does remote ischemic preconditioning reduce myocardial injury, acute kidney injury, or 6-month mortality in patients undergoing TAVI?
Remote ischemic preconditioning prior to TAVI does not provide cardio- or renoprotection, nor does it improve 6-month survival.
Background: Peri-interventional myocardial injury occurs frequently during transcatheter aortic valve implantation (TAVI). We assessed the effect of remote ischemic preconditioning (RIPC) on myocardial injury, acute kidney injury (AKIN) and 6-month mortality in patients undergoing TAVI. Methods: We performed a prospective single-center controlled trial. Sixty-six patients treated with RIPC prior to TAVI were enrolled in the study and were matched to a control group by propensity-score. RIPC was applied to the upper extremity using a conventional tourniquet. Myocardial injury was assessed using high-sensitive troponin-T (hsTnT), and kidney injury was assessed using serum creatinine levels. Data were compared with the Wilcoxon-Rank and McNemar tests. Mortality was analysed with the log-rank test. Results: TAVI led to a significant rise of hsTnT across all patients (p < 0.001). No significant inter-group difference in maximum troponin release or areas-under-the-curve was detected. Medtronic CoreValve and Edwards Sapien valves showed similar peri-interventional troponin kinetics and patients receiving neither valve did benefit from RIPC. AKIN occurred in one RIPC patient and four non-RIPC patients (p = 0.250). No significant difference in 6-month mortality was observed. No adverse events related to RIPC were recorded. Conclusion: Our data do not show a beneficial role of RIPC in TAVI patients for cardio- or renoprotection, or improved survival.
No takes yet. Share an insight, caveat, or question.
Flechsig et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: